Xenon Pharmaceuticals Inc...

30.70
-0.76 (-2.42%)
At close: Apr 03, 2025, 3:59 PM
30.71
0.05%
After-hours: Apr 03, 2025, 04:05 PM EDT

Xenon Pharmaceuticals Statistics

Share Statistics

Xenon Pharmaceuticals has 76.54M shares outstanding. The number of shares has increased by 1.42% in one year.

Shares Outstanding 76.54M
Shares Change (YoY) 1.42%
Shares Change (QoQ) 0.4%
Owned by Institutions (%) 97.9%
Shares Floating 74.21M
Failed to Deliver (FTD) Shares 158
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 2.89M, so 3.79% of the outstanding shares have been sold short.

Short Interest 2.89M
Short % of Shares Out 3.79%
Short % of Float 3.94%
Short Ratio (days to cover) 7.75

Valuation Ratios

The PE ratio is -13.03 and the forward PE ratio is -11.04. Xenon Pharmaceuticals's PEG ratio is -1.27.

PE Ratio -13.03
Forward PE -11.04
PS Ratio 0
Forward PS 3.3
PB Ratio 4.04
P/FCF Ratio -16.83
PEG Ratio -1.27
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Xenon Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.01.

Current Ratio 17.85
Quick Ratio 17.85
Debt / Equity 0.01
Debt / EBITDA -0.03
Debt / FCF -0.05
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-741.55K
Employee Count 316
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 4.09M
Effective Tax Rate -1.72%

Stock Price Statistics

The stock price has increased by -23.85% in the last 52 weeks. The beta is 1.26, so Xenon Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.26
52-Week Price Change -23.85%
50-Day Moving Average 37.3
200-Day Moving Average 39.69
Relative Strength Index (RSI) 30.89
Average Volume (20 Days) 458.82K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -279.3M
Net Income -234.33M
EBITDA -279.3M
EBIT n/a
Earnings Per Share (EPS) -3.01
Full Income Statement

Balance Sheet

The company has 142.71M in cash and 9.02M in debt, giving a net cash position of 133.7M.

Cash & Cash Equivalents 142.71M
Total Debt 9.02M
Net Cash 133.7M
Retained Earnings -899.47M
Total Assets 798.14M
Working Capital 599.67M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -181.39M and capital expenditures 0, giving a free cash flow of -181.39M.

Operating Cash Flow -181.39M
Capital Expenditures 0
Free Cash Flow -181.39M
FCF Per Share -2.33
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

XENE does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for XENE is $57.5, which is 82.8% higher than the current price. The consensus rating is "Buy".

Price Target $57.5
Price Target Difference 82.8%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score 33.81
Piotroski F-Score 1